Autres langues HLS Therapeutics Inc.

Actions

HLS

CA40390B1094

Marché Fermé - Toronto S.E. Autres places de cotation 20:13:29 06/05/2024			Varia. 5j.	Varia. 1 janv.
4,77 ^CAD	+0,42%		+2,58%	+20,76%

08/04	HLS Therapeutics Inc. annonce les résultats de l'analyse Reduce-IT concernant les effets de VASCEPA	CI
14/03	Transcript : HLS Therapeutics Inc., Q4 2023 Earnings Call, Mar 14, 2024

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call	25/04
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	08/04
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	08/04
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	14/03
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	14/03
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	14/03
HLS Therapeutics Announces Fiscal 2023 Financial Results	14/03
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	14/03
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call	29/02
HLS Announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	07/02
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	06/02
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	06/02
HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan	06/02
HLS Therapeutics Inc. Announces CFO Changes	18/12
HLS Therapeutics Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	18/12
HLS Therapeutics Brief: Announcing CFO Departure; John Hanna appointed Interim CFO to replace departing CFO Tim Hendrickson	18/12
HLS Therapeutics Announces CFO Departure	18/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues HLS Therapeutics Inc.

Actions

HLS

CA40390B1094

Autres langues

Filtres